Mounjaro NHS Cost Explained: What UK Patients Actually Pay

What NICE says about NHS eligibility, and why it shapes the cost question

The starting point for any honest answer about Mounjaro's NHS cost is the NICE appraisal published in December 2024. NICE's recommendations for tirzepatide (TA1026) set out a phased rollout based on BMI and the number of weight-related conditions a person has. From June 2025, adults with a BMI of 40 or above and four or more qualifying conditions (covering things like high blood pressure, type 2 diabetes, cardiovascular disease, obstructive sleep apnoea and dyslipidaemia) became eligible. A second cohort, BMI 35–39.9 with four or more conditions, opened in June 2026. Further phases follow. BMI thresholds are 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

For those who do qualify, the cost of the medicine itself is covered. In England, the only charge is the standard NHS prescription fee (currently £9.90 per prescription item) unless the patient holds a prepayment certificate or an exemption, in which case it's free. Scotland, Wales and Northern Ireland have their own arrangements and, in some cases, no prescription charge at all. What isn't free is the time. NHS waiting lists for specialist weight management services remain long in many areas, and GP practices can only take part in the new prescribing framework if they choose to, participation varies.

This is the gap that makes the cost question so common. Most people searching for Mounjaro's NHS cost have already found that they sit just outside the current phase, or they've been told their surgery isn't yet enrolling. If you want to understand how the Mounjaro NHS deal works, including what charges apply at each stage and what exemptions exist, that information can help clarify which cohort is open and which services your ICB commissions.

Private Mounjaro pricing: what the market looks like and what those numbers really cover

For people who go private, Mounjaro's cost reflects the dose and, critically, what the provider wraps around the medicine. In August 2025 Eli Lilly raised UK list prices substantially (the highest-dose pen moved from around £122 to around £330) and private prices across the market since then have typically ranged from roughly £149 to £375 per four-week pen, depending on strength and provider. Those figures are widely reported and should be treated as a guide, not a fixed market rate. They shift.

The more important question is what a headline price includes. A common misconception (and one worth letting go of) is that the cheapest listing simply means the same thing at a lower price. Often it doesn't. Some providers charge separately for the consultation, the prescription, delivery and any follow-up clinical contact. Add those together and a lower headline can become the more expensive option. A closer look at Mounjaro's overall cost shows how quickly those add-ons mount up over a course of treatment.

At nume, one transparent price covers the consultation, the prescription review, the medicine, next-working-day delivery and seven-day aftercare, nothing billed separately. We're not the cheapest option on the market, and that's a deliberate choice: clinical infrastructure, genuine supply-chain sourcing and a GPhC-registered pharmacy don't sit at the bottom of a price comparison. Every repeat order is clinically re-reviewed by a real prescriber. No subscription, no auto-renewal. Our current treatment pricing is shown on the treatment page.

Why 'cheapest' is the wrong test for a prescription medicine

Mounjaro is a prescription-only medicine, which means the clinical assessment behind the supply is not optional, it is legally required and clinically essential. The NHS guidance on tirzepatide covers why a prescriber needs to know your full health picture before starting treatment, and why ongoing review matters as doses increase. A lower price that skips a meaningful clinical assessment isn't a saving, it's a missing component.

The MHRA has warned publicly about counterfeit weight-loss pens being sold through social media and unverified websites, some containing harmful substances. Sellers offering these medicines without a prescription, or using discount codes to draw buyers in, are red flags the regulator specifically highlights. Any pharmacy supplying Mounjaro legitimately will be registered with the GPhC, you can check that directly at the GPhC register. Our own registration is publicly listed there. For a medicine taken weekly over months, the supply chain behind it matters more than a few pounds on the monthly bill.

If you're weighing the NHS route against going private, it's worth knowing how much Mounjaro is on the NHS before deciding which path suits your situation, and if you're trying to find competitive private options in your area, our guide to Mounjaro prices near me covers what local and online providers are currently charging. The next step, if you want a clinical view on your own situation, is a free consultation with one of our prescribers, no obligation, and you'll have an answer the same day. Start your free consultation here.